{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:32:49Z","timestamp":1791405169347,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"am","delay-in-days":272,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014475","name":"Pfizer Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016399","name":"Japan Osteoporosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bone.2022.116396","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T20:14:06Z","timestamp":1648325646000},"page":"116396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan"],"prefix":"10.1016","volume":"160","author":[{"given":"Masayuki","family":"Iki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nakatoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniyasu","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2022.116396_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"LoCascio","year":"1990","journal-title":"Bone Miner."},{"issue":"10","key":"10.1016\/j.bone.2022.116396_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study","volume":"119","author":"Laan","year":"1993","journal-title":"Annals of internal medicine"},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2022.116396_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2022.116396_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bone.2022.116396_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bone.2022.116396_bb0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.injury.2016.04.018","article-title":"Quality of life after hip fracture in the elderly: a systematic literature review","volume":"47","author":"Peeters","year":"2016","journal-title":"Injury"},{"issue":"26","key":"10.1016\/j.bone.2022.116396_bb0040","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2022.116396_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.11005\/jbm.2020.27.4.247","article-title":"Intervention thresholds for treatment in patients with glucocorticoid-induced osteoporosis: systematic review of guidelines","volume":"27","author":"Lee","year":"2020","journal-title":"J. Bone Metab."},{"issue":"8","key":"10.1016\/j.bone.2022.116396_bb0055","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J. Bone Miner. Metab."},{"issue":"3-4","key":"10.1016\/j.bone.2022.116396_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7223\/apjdm.6.55","article-title":"The claim database in Japan","volume":"6","author":"Matsuda","year":"2012","journal-title":"Asian Pacific Journal of Disease Management"},{"key":"10.1016\/j.bone.2022.116396_bb0070","series-title":"Proportion of Electronic Claims in the Japanese Health Insurance System","year":"2016"},{"key":"10.1016\/j.bone.2022.116396_bb0075","series-title":"NDB Open Data","year":"2017"},{"issue":"1","key":"10.1016\/j.bone.2022.116396_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1016\/j.bone.2022.116396_bb0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jclinepi.2012.10.004","article-title":"The validity of administrative data to identify hip fractures is high\u2013a systematic review","volume":"66","author":"Hudson","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.bone.2022.116396_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-021-06265-y","article-title":"Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study","author":"Iki","year":"2022","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2022.116396_bb0095","first-page":"e486","article-title":"Osteoporosis management among chronic glucocorticoid users: a systematic review","volume":"21","author":"Albaum","year":"2014","journal-title":"Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique"},{"issue":"2","key":"10.1016\/j.bone.2022.116396_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00198-005-2030-1","article-title":"Anti-vertebral fracture efficacy of raloxifene: a meta-analysis","volume":"17","author":"Seeman","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1210\/er.2001-8002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women","volume":"23","author":"Papadimitropoulos","year":"2002","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","article-title":"A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2013a randomized, active comparator, double-blind study","volume":"49","author":"Matsumoto","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2022.116396_bb0115","article-title":"Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures","volume":"105","author":"Ding","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"17","key":"10.1016\/j.bone.2022.116396_bb0120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bone.2022.116396_bb0125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1843.2004.00637.x","article-title":"COPD in Japan: the Nippon COPD Epidemiology study","volume":"9","author":"Fukuchi","year":"2004","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"5","key":"10.1016\/j.bone.2022.116396_bb0130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1378\/chest.07-1092","article-title":"Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids","volume":"132","author":"Vestergaard","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.bone.2022.116396_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/1479973119838280","article-title":"Mortality and vertebral fracture risk associated with long-term oral steroid use in patients with chronic obstructive pulmonary disease: a systemic review and meta-analysis","volume":"16","author":"Chang","year":"2019","journal-title":"Chron. Respir. Dis."},{"issue":"5","key":"10.1016\/j.bone.2022.116396_bb0140","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1183\/09031936.05.00058204","article-title":"Severity of obstructive airway disease and risk of osteoporotic fracture","volume":"25","author":"de Vries","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bone.2022.116396_bb0145","series-title":"Results of National Survey of Hip Fracture in 2019","year":"2019"},{"issue":"2","key":"10.1016\/j.bone.2022.116396_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989","volume":"7","author":"Cooper","year":"1992","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:59:44Z","timestamp":1757613584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"alternative-id":["S8756328222000722"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116396","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116396"}}